Challenges and Limitations in the Interpretation of Systematic Reviews: Making Sense of Clopidogrel and CYP2C19 Pharmacogenetics
作者： M J Sorich , T M Polasek , M D Wiese
关键词:
摘要: From 2010 to 2012, nine systematic reviews reported highly variable conclusions regarding the association between carriage of a cytochrome P450 2C19 loss-of-function allele and risk adverse cardiovascular (CV) events in individuals using clopidogrel. Possible contributors findings include differences patient populations, CV end points, statistical models utilized by reviews, as well unexplained heterogeneity, inconsistent/incomplete reporting, publication bias with respect primary studies. Clinical Pharmacology & Therapeutics (2013); 94 3, 376–382. doi:10.1038/clpt.2013.100
nature.com
sci-hub.se 参考文章(63)
T. Bauer, H. J. Bouman, J. W. van Werkum, N. F. Ford, J. M. ten Berg, D. Taubert, Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis BMJ. ,vol. 343, pp. 4588- 4588 ,(2011) , 10.1136/BMJ.D4588
Jae-Sik Jang, Kyoung-Im Cho, Han-Young Jin, Jeong-Sook Seo, Tae-Hyun Yang, Dae-Kyeong Kim, Dong-Soo Kim, Sang-Hoon Seol, Doo-Il Kim, Bo-Hyun Kim, Yong Hyun Park, Hyung-Gon Je, Young-Hoon Jeong, Seung-Whan Lee, Meta-Analysis of Cytochrome P450 2C19 Polymorphism and Risk of Adverse Clinical Outcomes Among Coronary Artery Disease Patients of Different Ethnic Groups Treated With Clopidogrel The American Journal of Cardiology. ,vol. 110, pp. 502- 508 ,(2012) , 10.1016/J.AMJCARD.2012.04.020
Lukasz A. Malek, Bartlomiej Kisiel, Mateusz Spiewak, Marcin Grabowski, Krzysztof J. Filipiak, Grazyna Kostrzewa, Zenon Huczek, Rafal Ploski, Grzegorz Opolski, Coexisting Polymorphisms of P2Y12 and CYP2C19 Genes as a Risk Factor for Persistent Platelet Activation With Clopidogrel Circulation Journal. ,vol. 72, pp. 1165- 1169 ,(2008) , 10.1253/CIRCJ.72.1165
R D Riley, W Sauerbrei, D G Altman, Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. British Journal of Cancer. ,vol. 100, pp. 1219- 1229 ,(2009) , 10.1038/SJ.BJC.6604999
Ryo Nisho, Toshiro Shinke, Junya Shite, Takahiro Sawada, Ryuji Toh, Yoko Haraguchi, Hiromasa Otake, Daisuke Matsumoto, Hiroyuki Kawamori, Masayuki Nakagawa, Ryoji Nagoshi, Amane Kozuki, Takumi Inoue, Hirotoshi Hariki, Yu Taniguchi, Noritoshi Hiranuma, Ken-ichi Hirata, IMPACT OF CYTOCHROME P450 2C19*2 POLYMORPHISM ON THE TARGET LESION OUTCOME AFTER DRUG-ELUTING STENT IMPLANTATION IN JAPANESE PATIENTS RECEIVING CLOPIDOGREL. Journal of the American College of Cardiology. ,vol. 57, ,(2011) , 10.1016/S0735-1097(11)61299-0
C Y Lu, J Karnon, M J Sorich, The Importance of High‐Quality Evidence of the Long‐Term Impact of Nonfatal Events Used in Randomized Controlled Trials: A Case Study of Prasugrel Clinical Pharmacology & Therapeutics. ,vol. 90, pp. 27- 29 ,(2011) , 10.1038/CLPT.2011.61
Lars Wallentin, Genetic substudy of the PLATO trial – Authors' reply The Lancet. ,vol. 377, pp. 637- 638 ,(2011) , 10.1016/S0140-6736(11)60228-6
Jessica L Mega, David A Morrow, James A de Lemos, Satishkumar Mohanavelu, Christopher P Cannon, Marc S Sabatine, None, Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes. Journal of the American College of Cardiology. ,vol. 51, pp. 2422- 2429 ,(2008) , 10.1016/J.JACC.2008.01.069
Michael J. Sorich, Ross A. McKinnon, Personalized medicine: potential, barriers and contemporary issues. Current Drug Metabolism. ,vol. 13, pp. 1000- 1006 ,(2012) , 10.2174/138920012802138615
Ghada Abo-Zaid, Willi Sauerbrei, Richard D Riley, Individual participant data meta-analysis of prognostic factor studies: state of the art? BMC Medical Research Methodology. ,vol. 12, pp. 56- 56 ,(2012) , 10.1186/1471-2288-12-56